Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KPTI by emailGet an email when KPTI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KPTI, unsubscribe in one click. Privacy
📣 What KPTI Says Is Next
fourth quarter of 2026 · “The Company expects to receive notice of the FDA’s decision on sNDA filing acceptance and, if accepted, the anticipated review timelines in the fourth quarter of 2026, following the FDA’s 60-day filing review period.”
Company press release, Aug 31, 2026 · SEC filing
second half of 2026 · “Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026. 2026 Financial Outlook Based on its current operating plans, Karyopharm expects the following for full year 2026:”
Company press release, Aug 13, 2026 · SEC filing
second half of 2026 · “Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KPTI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KPTI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.